Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
- Written by ACN Newswire - Press Releases
.
More Articles ...
- Central Global Berhad's Proposed Private Placement Approved by Bursa Securities
- Tim Da Jeweler Announces His Remarkable Custom Hats Laced With Hand Set Diamonds
- Toyota Gazoo Racing Hyped For Hypercar Debut
- Moonstake Hosts Joint Interview with CEO of Trusted Ranking Platform Staking Rewards, Mirkos Schmiedl
- Pertama Digital expresses interest to apply for BNM's digital banking license, currently in talks to form dedicated consortium
- Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally
- Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
- Insider Protocol Goes to Binance Launchpad with Hedge Funds Partnerships
- Avance Clinical Invited to Present Decentralized Trials - No Going Back for Oracle Health Sciences Connect
- Honda e Triumphs at 2021 World Car Awards
Magazine
Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know
Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...
Common Risks Hidden in Commercial Lease Agreements
Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...
Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake
Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...